Well, things are winding to a close. I
have several more postings that are still in draft version, but it's not
too soon to make the obvious conclusion about the seminar:
1. Copyright got a fair shake and managed to get several excellent speakers to defend the importance of copyright.
2. Patent, on the other hand, got rolled. Particularly the pharmaceutical industry.
I don't know why. No doubt the pharma folks have a tougher sell. But they also have the most to lose. More likely, the copyright community worked hard to make sure that they had people on the panels, while the pharma folks wrote the whole thing off. At least, it looks like they wrote it off. They certainly did not have a presence on the program.
That's too bad. Because we all have a great deal to lose if the pharmaceutical industry loses. And right now, the pharmaceutical industry is losing.
1. Copyright got a fair shake and managed to get several excellent speakers to defend the importance of copyright.
2. Patent, on the other hand, got rolled. Particularly the pharmaceutical industry.
I don't know why. No doubt the pharma folks have a tougher sell. But they also have the most to lose. More likely, the copyright community worked hard to make sure that they had people on the panels, while the pharma folks wrote the whole thing off. At least, it looks like they wrote it off. They certainly did not have a presence on the program.
That's too bad. Because we all have a great deal to lose if the pharmaceutical industry loses. And right now, the pharmaceutical industry is losing.